Who are APL-1202 treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pf-06865571, Pf-06823859, HyperAcute-Pancreas Immunotherapy, TQB2303, MAZ-101association, SPARC1104 modified dose regimen I.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apl-1202-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

APL-1202 treatment — Competitive Intelligence Brief

APL-1202 treatment (APL-1202 treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

phase 2 PD-1/PD-L1 inhibitor PD-1/PD-L1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

APL-1202 treatment (APL-1202 treatment) — Jiangsu Yahong Meditech Co., Ltd aka Asieris. APL-1202 treatment targets the PD-1/PD-L1 pathway to modulate the immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
APL-1202 treatment TARGET	APL-1202 treatment	Jiangsu Yahong Meditech Co., Ltd aka Asieris	phase 2	PD-1/PD-L1 inhibitor	PD-1/PD-L1
Pf-06865571	pf-06865571	Pfizer	marketed	Monoclonal antibody	PD-1/PD-L1 pathway
Pf-06823859	pf-06823859	Pfizer	marketed	Monoclonal Antibody	PD-1/PD-L1
HyperAcute-Pancreas Immunotherapy	HyperAcute-Pancreas Immunotherapy	NewLink Genetics Corporation	phase 3	Cancer immunotherapy vaccine combination	Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway
TQB2303	TQB2303	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
MAZ-101association	MAZ-101association	EMS	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
SPARC1104 modified dose regimen I	SPARC1104 modified dose regimen I	Sun Pharma Advanced Research Company Limited	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
AstraZeneca · 2 drugs in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Hanlim Pharm. Co., Ltd. · 1 drug in this class
EMD Serono · 1 drug in this class
EMS · 1 drug in this class
Fujian Cancer Hospital · 1 drug in this class
Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
Cellvax Therapeutics Inc · 1 drug in this class
Anhui Shi, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). APL-1202 treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/apl-1202-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab